Increased levels of neurofilament light chain in suicide attempters' serum.
axonal damage
inflammation
neurofilament light chain
suicidal ideation
Journal
Translational neuroscience
ISSN: 2081-3856
Titre abrégé: Transl Neurosci
Pays: Germany
ID NLM: 101550327
Informations de publication
Date de publication:
01 Jan 2022
01 Jan 2022
Historique:
received:
03
04
2022
revised:
05
07
2022
accepted:
15
07
2022
entrez:
22
8
2022
pubmed:
23
8
2022
medline:
23
8
2022
Statut:
epublish
Résumé
A specific biological vulnerability underlies suicidal behavior. Recent findings have suggested a possible role of inflammation and neuroaxonal injury. However, the relationship between inflammation and clinical symptoms in this disorder is still unclear. The objective of this study is applying novel blood markers of neuroaxonal integrity such as neurofilament light chain (NfL) and comparing the results with the healthy control subjects. In this cross-sectional study patients with suicide attempts were evaluated. The serum concentration of NfL on admission was measured by enzyme-linked immunosorbent assays. A total of 50 patients with a suicide attempts and 35 healthy controls were included in the study. The levels of NfL in attempted suicide patients were significantly higher in comparison with healthy controls (40.52 ± 33.54 vs 13.73 ± 5.11, These findings indicate that axonal damage may be an underlying neuropathological component of suicide attempt patients, although no correlation was observed with clinical features. This line of work could lead to new horizons in understanding the neurobiology of suicidal attempts and the development of better management strategies for these patients.
Sections du résumé
Background
UNASSIGNED
A specific biological vulnerability underlies suicidal behavior. Recent findings have suggested a possible role of inflammation and neuroaxonal injury. However, the relationship between inflammation and clinical symptoms in this disorder is still unclear. The objective of this study is applying novel blood markers of neuroaxonal integrity such as neurofilament light chain (NfL) and comparing the results with the healthy control subjects.
Methods
UNASSIGNED
In this cross-sectional study patients with suicide attempts were evaluated. The serum concentration of NfL on admission was measured by enzyme-linked immunosorbent assays.
Results
UNASSIGNED
A total of 50 patients with a suicide attempts and 35 healthy controls were included in the study. The levels of NfL in attempted suicide patients were significantly higher in comparison with healthy controls (40.52 ± 33.54 vs 13.73 ± 5.11,
Conclusion
UNASSIGNED
These findings indicate that axonal damage may be an underlying neuropathological component of suicide attempt patients, although no correlation was observed with clinical features. This line of work could lead to new horizons in understanding the neurobiology of suicidal attempts and the development of better management strategies for these patients.
Identifiants
pubmed: 35990554
doi: 10.1515/tnsci-2022-0236
pii: tnsci-2022-0236
pmc: PMC9356285
doi:
Types de publication
Journal Article
Langues
eng
Pagination
218-223Informations de copyright
© 2022 Mahtab Ramezani et al., published by De Gruyter.
Déclaration de conflit d'intérêts
Conflict of interest: Authors state no conflict of interest.
Références
Front Cell Neurosci. 2018 Jan 30;12:24
pubmed: 29440995
Cold Spring Harb Perspect Biol. 2017 Apr 3;9(4):
pubmed: 28373358
Brain Behav Immun. 2011 Feb;25(2):181-213
pubmed: 20970492
Lancet Psychiatry. 2014 Jun;1(1):63-72
pubmed: 26360403
Nat Rev Neurol. 2018 Oct;14(10):577-589
pubmed: 30171200
Acta Psychiatr Scand. 2008 Mar;117(3):198-206
pubmed: 18081924
Brain Behav Immun. 2015 May;46:203-11
pubmed: 25678163
Biol Psychiatry. 2013 Jul 1;74(1):15-25
pubmed: 23419545
Clin Sci (Lond). 2011 Nov;121(9):367-87
pubmed: 21745188
Front Psychiatry. 2018 Sep 25;9:451
pubmed: 30319458
Eur Arch Psychiatry Clin Neurosci. 2019 Jun;269(4):387-395
pubmed: 29980921
Biol Psychiatry. 2008 Apr 15;63(8):801-8
pubmed: 18005941
Neuron. 2016 Jul 6;91(1):1-3
pubmed: 27387643
Curr Psychiatry Rep. 2017 Jun;19(6):31
pubmed: 28470485
Neuropsychopharmacology. 2014 Sep;39(10):2349-56
pubmed: 24694925
J Psychiatr Res. 2014 Jun;53:62-8
pubmed: 24565447
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jul 13;93:1-10
pubmed: 30849414
World J Biol Psychiatry. 2000 Jan;1(1):17-25
pubmed: 12607229
Neuropsychopharmacology. 2012 Jan;37(1):137-62
pubmed: 21918508
J Affect Disord. 2013 Sep 25;150(3):736-44
pubmed: 23870425
J Am Assoc Nurse Pract. 2014 Nov;26(11):629-637
pubmed: 24715687
Brain Behav Immun. 2017 Oct;65:195-201
pubmed: 28483660
JAMA Neurol. 2019 Nov 01;76(11):1359-1366
pubmed: 31403661
J Interferon Cytokine Res. 2019 Mar;39(3):181-189
pubmed: 30844329
Psychoneuroendocrinology. 2008 Sep;33(8):1061-8
pubmed: 18672335
Neurology. 2019 Mar 5;92(10):e1007-e1015
pubmed: 30737333
CNS Neurosci Ther. 2012 Mar;18(3):201-7
pubmed: 22449107
Annu Rev Clin Psychol. 2016;12:307-30
pubmed: 26772209
JAMA Neurol. 2019 Sep 01;76(9):1035-1048
pubmed: 31206160
J Neuropathol Exp Neurol. 2014 Sep;73(9):880-90
pubmed: 25101704
Adv Clin Chem. 2020;96:179-216
pubmed: 32362318
Biol Psychiatry. 2010 Mar 1;67(5):446-57
pubmed: 20015486
Brain Behav Immun. 2014 Nov;42:50-9
pubmed: 24858659
Neurology. 2020 Jun 9;94(23):e2412-e2423
pubmed: 32461282
PLoS One. 2018 Feb 22;13(2):e0192998
pubmed: 29470514
J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):870-881
pubmed: 30967444
J Psychiatr Res. 2008 Jan;42(2):151-7
pubmed: 17174336
Biol Psychiatry. 2009 Aug 1;66(3):287-92
pubmed: 19268915
Ann Neurol. 2017 Jun;81(6):857-870
pubmed: 28512753
Nord J Psychiatry. 2008;62(6):431-5
pubmed: 18846444